Report Highlights

Who Controls the nr-AxSpA Market — and Who Is Challenging That

UCB and Novartis currently hold the most defensible positions in the nr-AxSpA therapeutic market. UCB secured the first EU approval specifically for nr-AxSpA with certolizumab pegol (Cimzia) in 2016 and has since stacked bimekizumab onto that franchise, creating a two-drug portfolio spanning TNF and IL-17A/F blockade. Novartis controls the IL-17A inhibitor segment with secukinumab (Cosentyx) and ixekizumab's market adjacency, supported by over a decade of real-world evidence in related spondyloarthropathy indications. Both companies maintain formulary access through established rheumatology relationships and long-term outcomes data that biosimilar entrants cannot immediately replicate.

AbbVie is the most credible challenger, deploying upadacitinib (Rinvoq), its JAK1-selective inhibitor, with an nr-AxSpA FDA approval secured in 2022. AbbVie's existing adalimumab patient base in axial spondyloarthritis gives it unmatched physician trust and contracting leverage to convert patients as they cycle off TNF therapy. For the competitive order to shift meaningfully, a next-generation IL-23 inhibitor with sustained remission data in nr-AxSpA would need to post Phase III results superior to bimekizumab's ASAS40 benchmarks — currently a two-to-three year horizon at minimum.

nr-AxSpA Therapeutic Dynamics: How the Market Operates Today

The nr-AxSpA therapeutic market operates through specialty pharmacy and hospital outpatient channels, with rheumatologists serving as the exclusive prescribing gatekeepers. Pricing is governed by annual biologic net prices ranging from USD 25,000 to USD 55,000 per patient in the United States, with payer formulary placement determined by clinical evidence dossiers, patient assistance program reach, and outcomes-based contract negotiations. Step therapy remains the dominant access structure: TNF inhibitors must fail before IL-17 or JAK inhibitors receive authorization in most major markets, which structurally protects the TNF segment and slows premium product uptake.

The market is in active maturation rather than early growth. Consolidation is already visible in the TNF inhibitor tier, where biosimilars of adalimumab and etanercept are compressing branded revenue while innovators pivot to next-generation mechanisms. Regulatory evolution is also reshaping operations: the EMA's progressive guidance on nr-AxSpA-specific trial endpoints — particularly the ASAS criteria and MRI inflammation scoring — has formalized what constitutes approvable evidence, reducing regulatory uncertainty for pipeline compounds while simultaneously raising the clinical bar for differentiation.

nr-AxSpA Therapeutic Demand Drivers

The primary demand driver is diagnostic reclassification. Prior to updated ASAS classification criteria gaining widespread clinical adoption, a substantial proportion of nr-AxSpA patients were misdiagnosed as having non-specific low back pain or fibromyalgia, leaving them untreated. Rheumatology societies in the US and EU have since launched structured education programs, and MRI access in primary care is expanding, shortening the historically nine-year diagnostic delay. Every year that delay compresses, the addressable treated population grows — an structural volume driver that is independent of pricing or competition.

The second driver is biologic cycling behavior among established axial spondyloarthritis patients. As ankylosing spondylitis patients accumulate years on TNF inhibitors and experience secondary non-response, rheumatologists are increasingly initiating therapy earlier in the nr-AxSpA disease stage to preserve joint integrity. This earlier intervention mandate, now embedded in ACR and EULAR guidelines, expands the treatment window per patient and increases lifetime biologic revenue per case. Third, gender-equity recognition in nr-AxSpA — the condition affects women at near-parity with men, unlike classical AS — is broadening referral patterns and increasing newly diagnosed female patient volume.

Restraints Limiting nr-AxSpA Therapeutic Growth

The most structurally damaging restraint is payer skepticism around nr-AxSpA as a distinct reimbursable indication. In multiple European markets, national health technology assessment bodies — including NICE in England and G-BA in Germany — have questioned whether nr-AxSpA warrants separate, full-price reimbursement versus the AS indication, given diagnostic overlap. This has forced UCB and Novartis into price concessions and mandatory comparative effectiveness commitments that compress net margin on a per-patient basis and slow formulary access timelines by six to eighteen months in affected markets.

The second material restraint is the biosimilar erosion of TNF inhibitor revenue, which funds the R&D and commercial infrastructure that supports the nr-AxSpA franchise overall. With adalimumab biosimilars now exceeding 60% volume share in Europe and accelerating in the US post-2023 interchangeability designations, the profitability anchor for AbbVie's and Pfizer's broader rheumatology operations is deteriorating faster than next-generation nr-AxSpA assets can replace it. This creates a financial squeeze that delays investment in physician education, real-world evidence generation, and market access infrastructure — all of which are essential to growing a specialty indication like nr-AxSpA.

nr-AxSpA Therapeutic Opportunities

The most immediate opportunity lies in the US market, where the gap between estimated nr-AxSpA prevalence — roughly 0.7% of adults — and current diagnosed, treated patients represents a treatment penetration rate below 15%. Structured disease awareness campaigns combined with point-of-care MRI referral pathways, which several integrated health systems including Kaiser Permanente are piloting, can compress the diagnostic gap and convert latent demand into prescription volume within a three-to-five year horizon. Companies with existing rheumatology sales infrastructure will capture disproportionate share as this gap closes.

Japan and South Korea represent the highest-growth geographic opportunity outside the West. Both markets have updated national rheumatology guidelines to formally recognize nr-AxSpA, and Japan's PMDA approved secukinumab for the indication in 2021, opening the formulary pathway that competitors are now entering. South Korean reimbursement decisions for biologic nr-AxSpA therapy are pending, with a positive outcome projected to unlock a commercially attractive patient pool. Companies that build local real-world evidence registries in these markets before reimbursement is finalized will have a decisive advantage in HTA submissions.

Market at a Glance

nr-AxSpA Therapeutics by Region

North America is the largest regional market, driven by the United States, where biologic list prices remain uncapped and specialist physician density is high relative to patient volume. The US accounts for an estimated 58% of global nr-AxSpA biologic revenue, underpinned by AbbVie's Rinvoq and UCB's Cimzia maintaining strong formulary access across major pharmacy benefit managers. Canada's market is significantly smaller but growing as provincial formularies adopt nr-AxSpA-specific reimbursement criteria modeled on EMA approval language. Europe is the second-largest region, with Germany, France, and the UK generating the majority of biologic volume, though price controls and AMNOG negotiations cap net revenue growth meaningfully below volume growth rates.

Asia Pacific is the fastest-growing region, driven by Japan's established reimbursement framework and South Korea's forthcoming formulary decisions. China remains an early-stage market where domestic biosimilar TNF inhibitors dominate and imported biologic penetration is constrained by NMPA approval timelines, but the sheer scale of the undiagnosed population makes it a critical long-term target. Latin America and the Middle East and Africa together represent a small but emerging commercial frontier; Brazil and Saudi Arabia show the most structured reimbursement pathways, though public tender pricing compresses margins. Overall, regional revenue distribution will shift materially toward Asia Pacific over the 2026–2034 forecast period.

Leading Market Participants

• UCB S.A.
• Novartis AG
• AbbVie Inc.
• Pfizer Inc.
• Eli Lilly and Company
• Johnson & Johnson (Janssen)
• Bristol Myers Squibb
• Sun Pharma
• Galapagos NV
• MoonLake Immunotherapeutics

Competitive Outlook for nr-AxSpA Therapeutics

Over the next five years, the nr-AxSpA competitive structure will bifurcate between a commoditized TNF inhibitor tier — dominated by biosimilars and subject to aggressive payer substitution — and a premium innovative tier where IL-17A/F dual inhibitors, selective JAK1 inhibitors, and emerging IL-23 antagonists compete on clinical differentiation and outcomes data. The innovative tier will consolidate around three to four dominant franchises; the TNF tier will fragment further as additional biosimilar entrants drive price compression below the threshold of commercial viability for smaller branded players. Companies without a next-generation mechanism in their nr-AxSpA pipeline by 2027 will lose formulary relevance in the premium segment.

The single most important competitive development to watch is MoonLake Immunotherapeutics' sonelokimab, a nanobody targeting IL-17A and IL-17F with a novel structural profile. If Phase III data confirm superiority over current IL-17 standards in nr-AxSpA — readouts expected in 2026 — MoonLake will either emerge as a disruptive standalone competitor or become an acquisition target for a larger player seeking to defend share against UCB's bimekizumab. Either outcome reshapes the premium segment's competitive map and forces Novartis and AbbVie to accelerate their own next-generation mechanism timelines or accept formulary displacement in key markets.